Pyxis Oncology, Inc.
PYXS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001782223
In the last 90 days, Pyxis Oncology, Inc. insiders filed 1 open-market purchase and 0 sales; 76 institutions reported holding it in 13F filings for Q2 2026, worth $101.1M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $195.0M
- Insider buysOpen market, last 90 days
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −1 vs. previous quarter
- 76
- 13F valueReported value at the end of Q2 2026
- $101.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $13.9M
- −14.2% year over year
- Net income, FY2025
- -$79.6M
- No comparable prior period
- Free cash flow, FY2025
- -$63.5M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $79.6M (574.5% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 4.35M
- Shares sold short
- Change
- −540.7K
- −11.1% vs. previous
- Days to cover
- 3.47
- At average daily volume
Superinvestors holding PYXS, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding PYXS at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Pyxis Oncology, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 9, 2026 (view filing)2:39 PM ET | Oct 1 | 8 days | GordonMD Global Investments LP and 3 others10% Owner | PPurchase | +7.17M | – | – | –7.17M after | AmendedDerivative |
| Oct 2, 2026 (view filing)8:35 AM ET | Oct 1 | 1 day | GordonMD Global Investments LP and 3 others10% Owner | PPurchaseCommon Stock, par value $0.001 per share ("Common Stock") | +5.52M | – | – | +55.0%15.5M after | From original |
| Jul 2, 2026 (view filing)4:30 PM ET | Jun 30 | 2 days | Dupont JakobDirector | SSale | −35.0K | $3.06 | −$107.1K | −47.5%38.7K after | 10b5-1 |
| Mar 25, 2026 (view filing) | Apr 14-21, 2025 | 345 daysLate | Humphrey RachelDirector | SSale | −15.5K | $1.02 | −$15.9K | −16.0%81.3K after | 3 lots10b5-1 |
| Nov 27, 2024 (view filing) | Nov 26 | 1 day | Yanchik Connealy PamelaCFO & COO | PPurchase | +88.8K | $1.96 | +$174.4K | +8.0%1.20M after | 2 lots |
| Sep 28, 2023 (view filing) | Sep 28 | Same day | Yanchik Connealy PamelaCFO and COO | PPurchase | +8.00K | $1.87 | +$15.0K | +1.0%818.5K after | |
| Sep 27, 2023 (view filing) | Sep 27 | Same day | Wadhane JitendraChief Accounting Officer | PPurchase | +2.50K | $1.87 | +$4.67K | +1.1%226.9K after | |
| Sep 27, 2023 (view filing) | Sep 27 | Same day | Yanchik Connealy PamelaCFO and COO | PPurchase | +6.43K | $1.85 | +$11.9K | +0.8%810.5K after | |
| Sep 25, 2023 (view filing) | Sep 25 | Same day | Wadhane JitendraChief Accounting Officer | PPurchase | +5.00K | $1.77 | +$8.85K | +2.3%224.4K after | |
| Sep 25, 2023 (view filing) | Sep 25 | Same day | Yanchik Connealy PamelaCFO and COO | PPurchase | +12.0K | $1.67 | +$20.0K | +1.5%804.1K after |
Top 10 13F holders, Q2 2026
See all 76 holdersThe largest institutional positions in Pyxis Oncology, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| GordonMD Global Investments LP | 10,024,909 | $30.2M | 16.57% | +5,903,039+143.2% | Added |
| Pfizer Inc | 7,032,770 | $19.5M | 11.43% | 00.0% | Unchanged |
| Laurion Capital Management LP | 4,900,888 | $14.8M | 1.07% | −96,445−1.9% | Reduced |
| Vanguard Capital Management LLC | 2,075,997 | $6.25M | 0.00% | +42,487+2.1% | Added |
| HealthInvest Partners AB | 966,459 | $2.91M | 0.78% | +769,423+390.5% | Added |
| BlackRock, Inc. | 867,934 | $2.61M | 0.00% | +79,095+10.0% | Added |
| Palo Alto Investors LP | 864,277 | $2.60M | 0.36% | −146,233−14.5% | Reduced |
| Marshall Wace, LLP | 830,544 | $2.50M | 0.00% | +476,127+134.3% | Added |
| Renaissance Technologies LLC | 772,232 | $2.32M | 0.00% | −116,448−13.1% | Reduced |
| Geode Capital Management, LLC | 591,849 | $1.78M | 0.00% | −6,272−1.0% | Reduced |
Holders of 5% or more of PYXS
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Pyxis Oncology, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| GordonMD Global Investments LP | 13G/A | 16.40%20.4M shares | −1.10 ppfrom 17.50% | Sep 23, 20254 filings | Oct 9, 2026 | SEC |
| Sullivan Lara | 13D/A | 11.21%7.54M shares | +0.91 ppfrom 10.30% | Oct 22, 20216 filings | Apr 2, 2025 | SEC |
| Biotechnology Value Fund L P | 13G | 9.99%8.34M shares | – | Dec 20, 20214 filings | Jul 10, 2026 | SEC |
| Coastlands Capital LP | 13G | 5.42%6.45M shares | New | Oct 5, 20261 filing | Oct 5, 2026 | SEC |
| Laurion Capital Management LP | 13G/A | 5.16%4.30M shares | −2.56 ppfrom 7.72% | Feb 8, 20234 filings | Nov 3, 2026 | SEC |